X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
OBT076 is a experimental CD205/Ly75-directed ADC which is currently being evaluated in phase 1 clinical trials for the treatment of Adenoid Cystic Carcinoma of the Head and Neck.
Lead Product(s): MEN1309
Therapeutic Area: Oncology Product Name: OBT076
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in Combination with CPI Balstilimab for patients with advanced solid tumors.
Lead Product(s): MEN1309,Balstilimab
Therapeutic Area: Oncology Product Name: OBT076
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
The collaboration aims to investigate OBT076, an ADC utilizing an ImmunoGen toxin in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck. The trial will investigate OBT076 as monotherapy and in sequence with balstilimab.
Lead Product(s): MEN1309
Therapeutic Area: Oncology Product Name: OBT076
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: GORTEC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 19, 2023
Details:
OBT076 (MEN1309) showed preliminary signs of clinical activity as a monotherapy, with objective responses including long lasting stable disease in six patients, in chemotherapy and checkpoint inhibitor (CPI) refractory patients.
Lead Product(s): MEN1309
Therapeutic Area: Oncology Product Name: OBT076
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Initial data from the Phase 1 dose escalation part of the OBT076 (MEN1309) trial in adult patients with advanced solid tumors indicated that OBT076 had a favorable tolerability profile; recommended dose was defined at 3.0 mg/kg.
Lead Product(s): MEN1309,Undisclosed
Therapeutic Area: Oncology Product Name: MEN1309
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
Under the terms of the agreement, OBT will be the sponsor of the combination trial of OBT076 with the anti-PD1 checkpoint inhibitor (CPI) balstilimab and responsible for operational execution, and Agenus will provide drug supply and scientific support.
Lead Product(s): MEN1309,Balstilimab
Therapeutic Area: Oncology Product Name: MEN1309
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Agenus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 25, 2021
Details:
Boehringer Ingelheim drug candidates are two of several assets approaching or in clinical development whose discovery has been enabled by OBT’s proprietary OGAP® target discovery platform.
Lead Product(s): MEN1309
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
